The failure of torcetrapib: is there a case for independent preclinical and clinical testing? – author's reply

Author： Doggrell Sheila A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.14, 2008-10, pp. : 2563-2564

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The failure of torcetrapib: is there a case for independent preclinical and clinical testing? – correspondence

By Shear Charles L  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 14, 2008-10 ,pp. : 2561-2562

Informa Healthcare

Access to resources Recommend Favorite

Aurora kinase inhibitors in preclinical and clinical testing

By Cheung Chun Hei Antonio   Coumar Mohane Selvaraj   Hsieh Hsing-Pang   Chang Jang-Yang  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 379-398

Informa Healthcare

Access to resources Recommend Favorite

Zebrafish As a Genetic Model in Pre-Clinical Drug Testing and Screening

By  

Current Medicinal Chemistry, Vol. 20, Iss. 19, 2013-06 ,pp. : 2458-2466

Bentham Science Publishers

Access to resources Recommend Favorite

The Author's Reply

By Ronaldson Kathlyn J.  

Drug Safety, Vol. 29, Iss. 12, 2006-01 ,pp. : 1191-1192

Adis International

Access to resources Recommend Favorite

The Author's Reply

By Block Adam E.  

PharmacoEconomics, Vol. 26, Iss. 7, 2008-01 ,pp. : 567-568

Adis International

Access to resources Recommend Favorite